Idasanutlin与navitoclax在T细胞急性淋巴细胞白血病中诱导协同性凋亡性细胞死亡
本文为临床前研究,在T-ALL细胞系、PDX及异种移植模型中评估MDM2抑制剂idasanutlin与BH3模拟物navitoclax的联合效果。体外联合较venetoclax诱导更一致且强效的协同杀伤,体内四个异种移植模型均见协同反应且联合组总生存显著延长。作者认为该联合在T-ALL中高度活跃,或可考虑用于临床。
要点
- idasanutlin单药在T-ALL细胞中仅诱导适度凋亡,但上调促凋亡BH3基因BAX与BBC3。
- idasanutlin联合navitoclax在体外对T-ALL PDX细胞系的协同杀伤比venetoclax更一致且强效。
- 体内四个T-ALL异种移植模型均见联合协同反应,联合组总生存显著延长。
核心结论
- 临床前数据显示idasanutlin联合navitoclax在T-ALL中高度活跃,作者认为或可考虑用于临床。
研究设计与样本
- 临床前研究,在T-ALL细胞、PDX细胞系及四个T-ALL异种移植模型中进行体外和体内评估。
主要发现
- idasanutlin单药在T-ALL细胞中仅诱导适度凋亡,但上调促凋亡BH3结构域基因BAX和BBC3。
- idasanutlin联合navitoclax在体外对T-ALL PDX细胞系的协同杀伤比Bcl-2特异性抑制剂venetoclax更一致且强效。
- 体内四个T-ALL异种移植模型均见idasanutlin联合navitoclax的明显协同反应,联合组总生存显著延长。
临床怎么用
- 作者在结论中提出,idasanutlin联合navitoclax在T-ALL中高度活跃,或可考虑用于临床。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy in which activating mutations in the Notch pathway are thought to contribute to transformation, in part, by activating c-Myc. Increased c-Myc expression induces oncogenic stress that can trigger apoptosis through the MDM2-p53 tumor suppressor pathway. Since the great majority of T-ALL cases carry inactivating mutations upstream in this pathway but maintain wildtype MDM2 and TP53, we hypothesized that T-ALL would be selectively sensitive to MDM2 inhibition. Treatment with idasanutlin, an MDM2 inhibitor, induced only modest apoptosis in T-ALL cells but upregulated the pro-apoptotic BH3 domain genes BAX and BBC3, prompting us to evaluate the combination of idasanutlin with BH3 mimetics. Combination treatment with idasanutlin and navitoclax, a potent Bcl-2/Bcl-xL inhibitor, induces more consistent and potent synergistic killing of T-ALL PDX lines in vitro than venetoclax, a Bcl-2 specific inhibitor. Moreover, a marked synergic response to combination treatment with idasanutlin and navitoclax was seen in vivo in all four T-ALL xenografts tested, with a significant increase in overall survival in the combination treatment group. Collectively, these preclinical data show that the combination of idasanutlin and navitoclax is highly active in T-ALL and may merit consideration in the clinical setting.
引用
- Johansson KB, Zimmerman MS, Dmytrenko IV, et al. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2023. PMID: 37838759. doi:10.1038/s41375-023-02057-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。